HORIZON-HLTH-2025-01-TOOL-05:
Boosting the translation of biotech research into innovative health therapies (RIA)
Deadline: 16.09.2025
Eligibility conditions:
♦ Regulatory Approval for Clinical Testing:
Proposals must provide evidence of regulatory approval in the EU already in place for phase I clinical study.
♦ EU Contribution to Small and Medium-sized Enterprises:
The EU contribution allocated to small and medium-sized enterprises (SMEs) must constitute at least 50% of the total EU contribution to the entire project.
♦ Consortium Composition:
The consortium must be composed of at most 5 legal entities as beneficiaries.
